Astellas licenses Frequency’s lead drug for $625m 22-Jul-2019 By Ben Hargreaves Astellas agrees a deal for the ex-US rights of Frequency’s lead drug candidate, FX-322, after the latter company posted positive results in a Phase I/II trial.